Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1638 1653
This examiner grants 62% of resolved cases
Michael D. Burkhart is an examiner in Tech Center 1600 and Art Unit 1633. He has a substantial track record with 839 resolved cases. His allowance rate is 62.3 percent. This 62.3 percent rate indicates the likelihood of a grant for applications assigned to his docket in Art Unit 1633.
The data shows the impact of interviews on the outcome of prosecution. The interview lift is 11.7 percent. While an 11.7 percent lift indicates a positive correlation between interviews and allowances, the effect is specific to the 839 resolved cases in this profile. Practitioners should consider this 11.7 percent lift when deciding whether to engage in oral advocacy to resolve outstanding rejections.
The median days to allowance is 1216. This 1216 day figure represents the typical duration of the prosecution process from filing to grant. The 1216 day median provides a clear expectation for the time required to reach a successful outcome. Applicants can use these metrics to plan their intellectual property budgets and timelines effectively in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18658913 | Reprogrammed T Cell-Like NK Cells | Non-Final OA | NantBio, Inc. |
| 18695158 | METHODS FOR DELAYING CRISPR ACTION AND IMPROVING GENE DRIVE EFFECTIVENESS | Non-Final OA | The Regents of the University of California |
| 17777741 | COMPOSITIONS AND METHODS OF USING ENGINEERED FUSION PROTEINS THAT BIND G4C2 HUMAN REPEATS | Non-Final OA | The Regents of the University of California |
| 18628222 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17559934 | METHOD FOR THE PRODUCTION OF AN ANTIBODY | Final Rejection | Hoffmann-La Roche Inc. |
| 17929574 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION | Non-Final OA | Colorado State University Research Foundation |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | Non-Final OA | City of Hope |
| 18644724 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | Final Rejection | Exuma Biotech Corp. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy